Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2018/10/015978
CTRI/2018/10/015978
Not yet recruiting
Phase 1

A pilot study to assess the effectiveness and safety of oral vitmain D versus low dose oral acitretin in congenital non syndromic ichthyosis

Department of Dermatology Venereology and Leprology0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Department of Dermatology Venereology and Leprology
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Department of Dermatology Venereology and Leprology

Eligibility Criteria

Inclusion Criteria

  • •1\.Non syndromic congenital ichthyosis patients regardless of age and sex.
  • •2\.Women of child bearing potential if using adequate contraception.
  • •3\.Patients with either normal vitamin D levels or low vitamin D levels not having any clinical or radiological manifestations of rickets.
  • •4\.Patients who can give valid consent.
  • •5\.Willing for monthly follow\-up visits for at least 6 months.

Exclusion Criteria

  • •1\.Ichthyosis vulgaris
  • •2\.XLRI involving less than 10% body surface area.
  • •3\.Pregnant and lactating mothers.
  • •4\.Systemic treatment within 4 weeks prior to the start of treatment phase.
  • •5\.Patients with hypercalcemia or high vitamin D, and significant renal or hepatic disease.
  • •6\.Patients with severe hypovitaminosis D affecting bone health as assessed clinically and radiologically.
  • •7\.Inability to come for monthly follow up visits for 6 months
  • •8\.Those who cannot provide consent for the study

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
A Pilot study to evaluate the Efficacy and Safety of GFT505 orally administered once daily (30 mg) for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-controlled and randomized study.
EUCTR2007-004337-41-FRGENFIT30
Active, not recruiting
Phase 1
A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 35 days in patients presenting with impaired glucose tolerance and abdominal obesity. A double blind, parallel group, placebo-controlled and randomized study.patients presenting with impaired glucose tolerance and abdominal obesityMedDRA version: 9.1Level: LLTClassification code 10036481Term: Pre-diabetesMedDRA version: 9.1Level: LLTClassification code 10059179Term: Abdominal obesity
EUCTR2009-011003-23-FRGENFIT40
Active, not recruiting
Phase 1
A Pilot study to evaluate the Efficacy and Safety of GFT505 (80 mg) orally administered once daily for 28 days in atherogenic dyslipidaemic patients with abdominal obesity. A double blind, placebo-controlled and randomized study.Atherogenic dyslipidaemic patients with abdominal obesityMedDRA version: 9.1Level: LLTClassification code 10058108Term: DyslipidaemiaMedDRA version: 9.1Level: LLTClassification code 10059179Term: Abdominal obesity
EUCTR2008-005779-86-FRGENFIT90
Active, not recruiting
Phase 1
A Pilot study to evaluate the Efficacy and Safety of GFT505 (30 mg) orally administered for 28 days in patients with Frederickson Type IIb Dyslipidemia (Mixed Hyperlipidemia). A double blind, placebo-controlled and randomized study.
EUCTR2007-003237-16-FRGENFIT30
Active, not recruiting
Not Applicable
A Pilot study to evaluate the Efficacy and Safety of GFT505 (80mg) orally administered once daily for 12 weeks in patients with Type 2 Diabetes mellitus.A Multicentre, Randomised, Double Blind, Placebo-Controlled study.
EUCTR2010-021986-60-LVGENFIT120